Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

• Status: Completed
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National University of Malaysia
• Treatments: Plasminogen; Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

• adult patient with age more than 17 year old

• evidence of complex parapneumonic effusion or empyema; with poor pleural fluid drainage of ≤150 mL after 24 hours of insertion of chest drain

• clinical evidence of infection such as fever and or elevated C-reactive protein (CRP) or white-cell count

• complex pleural effusion proven by ultrasound

• pleural fluid analysis that fulfilled at least one of the characteristics: frank pus, exudative nature (according to light's criteria), gram stain or culture positive, lactate dehydrogenase (LDH) > 1000 U/L, pH < 7.2 and/or glucose level < 3.3mmol/L

Exclusion Criteria:

• known allergy to pulmozyme or alteplase

• acute stroke, active bleeding diathesis

• major surgery in past 5 days

• previous pneumonectomy on the infected side

• bronchopleural fistula

• pregnancy

• coagulopathy (INR > 2, APTT >100, platelet count < 50,000 cells)